BioNTech says gotistobart nearly doubles survival in lung cancer trial
BioNTech and OncoC4 said gotistobart nearly doubled median overall survival versus standard chemotherapy in previously treated squamous NSCLC in the first median-OS readout from a randomized Phase 3 trial. The result strengthens the drug’s clinical case, but the program remains investigational and the disclosed data come from a non-pivotal stage of the study.
The story
BioNTech and OncoC4 announced that gotistobart produced a median overall-survival result nearly twice that of standard-of-care chemotherapy in patients with squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. This update represents the first median-OS data from stage 1 of PRESERVE-003, a global randomized Phase 3 trial identified as NCT05671510, announced on September 14, 2026.
Gotistobart, also known as BNT316 or ONC-392, is an investigational CTLA-4-targeting immunotherapy. BioNTech and OncoC4 designed it to selectively deplete regulatory T cells within the tumor microenvironment.
The program connects BioNTech and OncoC4 through the jointly developed asset: BNT316 is BioNTech's designation, while ONC-392 is OncoC4's. The clinical opportunity is a previously treated squamous NSCLC population with progression after both immunotherapy and chemotherapy, a setting in which a survival advantage could support later regulatory and commercial development if the broader study confirms it.
The result is not yet a pivotal regulatory outcome. The companies described the readout as coming from the non-pivotal stage 1 portion of a Phase 3 trial.
The next evidence points are the full data presentation, additional results from PRESERVE-003 and any regulatory update. The key questions are whether the survival difference is statistically robust, whether it is accompanied by an acceptable safety profile, and whether the randomized Phase 3 program can reproduce the result in the intended treatment population.
Our read · Mon, Sep 14
The survival signal moves the clinical and partnering risk to the upside for BNTX, though the pivotal readout remains ahead.
Why. The readout improves the asset’s clinical value because a near-doubling of median overall survival in previously treated squamous NSCLC could strengthen BioNTech’s oncology pipeline and its relationship with OncoC4. The case is not yet directional enough for a dated trade call because the announcement omits the underlying survival figures, statistical detail, safety data and a next event date.
Both cases
What could change this view: The signal could weaken if the full dataset shows marginal statistical significance, materially worse safety, or failure to reproduce the survival benefit in the pivotal portion of PRESERVE-003.
Who reported it · 2
Keep reading
Latest on the Wire
Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →Latest on the Wire
Anthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by GlobeNewswire as BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
, . Who answers for this
2 reports from 1 publisher in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →